Synlogic is a clinical-stage biopharmaceutical company applying synthetic biology to the discovery and development of synthetic biotic. Co.'s pipeline includes: SYNB1934, which is an orally administered, non-systemically absorbed drug candidate based on a genetically engineered form of the probiotic E. coli Nissle; SYNB1353, which is a drug candidate designed to consume methionine, in the gastrointestinal (GI) tract thereby lowering homocysteine levels in patients with homocystinuria; SYNB8802, which is being developed for the treatment of enteric hyperoxaluria, a chronic, progressive disease; and SYNB2081, which is a synthetic biotic designed to consume uric acid in the GI tract.